Prognostic Role of Serum Lactate Dehydrogenase Beyond Initial Diagnosis: A Retrospective Analysis of Patients with Diffuse Large B Cell Lymphoma
| Autor: | Sanghui Park, Junshik Hong, Eun Kyung Cho, Hee Kyung Ahn, Sun Jin Sym, Pil Whan Park, Jae Hoon Lee, Dong Bok Shin, Jinny Park, Hyun Hwa Yoon, Jeong Yeal Ahn |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Pathology Gastroenterology Antibodies Monoclonal Murine-Derived chemistry.chemical_compound immune system diseases hemic and lymphatic diseases Internal medicine Lactate dehydrogenase Antineoplastic Combined Chemotherapy Protocols Humans Medicine Cyclophosphamide Aged Retrospective Studies Aged 80 and over L-Lactate Dehydrogenase biology business.industry Lymphoma Non-Hodgkin Retrospective cohort study Hematology General Medicine Middle Aged Prognosis medicine.disease Lymphoma Treatment Outcome chemistry Doxorubicin Vincristine Monoclonal biology.protein Prednisone Female Rituximab Lymphoma Large B-Cell Diffuse Antibody business Diffuse large B-cell lymphoma medicine.drug Serum lactate dehydrogenase |
| Zdroj: | Acta Haematologica. 130:305-311 |
| ISSN: | 1421-9662 0001-5792 |
| Popis: | Background/Aims: Baseline serum lactate dehydrogenase (LDH) level is a well-known prognostic factor in patients with non-Hodgkin's lymphoma; however, its role beyond initial diagnosis has not yet been defined. Methods: This study was conducted as a retrospective analysis of patients with diffuse large B cell lymphoma (DLBCL) treated with R-CHOP21, who had undergone regular checks for LDH during immunochemotherapy (n = 119) and during the posttreatment follow-up period after complete remission (CR; n = 100). The 119 patients were classified into 4 groups according to their baseline and change in LDH level during treatment, and an analysis of tumor response and survival was performed. The value of LDH as a predictor for relapse was evaluated among the patients with regular follow-up visits after achieving CR. Results: An increased LDH level during immunochemotherapy had no impact on tumor response or survival, and only the LDH status ‘before' treatment was a prognostic marker. The sensitivity, specificity, positive predictive value and negative predictive value of serum LDH for detecting relapse after CR were 47.4, 86.5, 9.3 and 98.3%, respectively. Conclusion: The measurement of LDH level beyond initial diagnosis has no clear benefit in predicting disease progression or relapse in patients with DLBCL treated with R-CHOP21. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|